Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (NCT06121180)
A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Who can join: Review the eligibility criteria below.
Location: The Angeles Clinic and Research Institute — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- The Angeles Clinic and Research Institute — Los Angeles, California
- Moffitt Cancer Center — Tampa, Florida
- University of Chicago Medical Center — Chicago, Illinois
- Northwell Health Center for Advanced Medicine — New Hyde Park, New York
📞 Contact the Study Coordinator
Phone: (813) 745-4482
Email: Indra.Herron@moffitt.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Uveal Melanoma
- Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma — Tampa, Florida
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Scottsdale, Arizona
- Vorinostat in Treating Patients With Metastatic Melanoma of the Eye — New York, New York
- A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas — Boston, Massachusetts
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — Los Angeles, California
- Tebentafusp-tebn With LDT in Metastatic UM — Philadelphia, Pennsylvania
Explore by condition: All Metastatic Uveal Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.